Skip to content
Methyl aminolevulinate
Metvixia (methyl aminolevulinate) is a small molecule pharmaceutical. Methyl aminolevulinate was first approved as Metvixia on 2004-07-27.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methyl aminolevulinate hydrochloride
Tradename
Company
Number
Date
Products
METVIXIAGaldermaN-021415 DISCN2004-07-27
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
metvixia2007-09-26
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XD: Sensitizers used in photodynamic/radiation therapy
— L01XD03: Methyl aminolevulinate
HCPCS
Code
Description
J7309
Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMETHYL AMINOLEVULINATE
INN—
Description
Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells. It has a role as an antineoplastic agent, a photosensitizing agent, a prodrug and a dermatologic drug. It is functionally related to a 5-aminolevulinic acid.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COC(=O)CCC(=O)CN
Identifiers
PDB—
CAS-ID33320-16-0
RxCUI337068
ChEMBL IDCHEMBL1096562
ChEBI ID724125
PubChem CID157922
DrugBankDB00992
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 650 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,197 adverse events reported
View more details